THAR
Tharimmune, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.54
+6.63%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -61.7%
- EPS
- +71.5%
- Free cash flow
- -47.9%
- Operating cash flow
- -47.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -61.7%
- Net income
- —
- EPS
- +88.1%
- Free cash flow
- -47.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025